» Articles » PMID: 38250075

Expert Consensus on the Use of Systemic Glucocorticoids for Managing Eosinophil-related Diseases

Abstract

Eosinophil-related diseases represent a group of pathologic conditions with highly heterogeneous clinical presentation and symptoms ranging from mild to critical. Both systemic and localized forms of disease are typically treated with glucocorticoids. The approval of novel biologic therapies targeting the interleukin-5 pathway can help reduce the use of systemic glucocorticoids (SGC) in eosinophilic diseases and reduce the risk of SGC-related adverse effects (AEs). In this article, a panel of experts from different medical specialties reviewed current evidence on the use of SGC in two systemic eosinophilic diseases: Eosinophilic Granulomatosis with PolyAngiitis (EGPA) and HyperEosinophilic Syndrome (HES); and in two single-organ (respiratory) eosinophilic diseases: Chronic RhinoSinusitis with Nasal Polyps (CRSwNP) and Severe Asthma with Eosinophil Phenotype (SA-EP), and contrasted it with their experience in clinical practice. Using nominal group technique, they reached consensus on key aspects related to the dose and tapering of SGC as well as on the initiation of biologics as SGC-sparing agents. Early treatment with biologics could help prevent AEs associated with medium and long-term use of SGC.

Citing Articles

Heterogeneity and individualized therapy for eosinophilic granulomatosis with polyangiitis.

Hua L, Xie M Ther Adv Respir Dis. 2025; 19:17534666251318615.

PMID: 39980304 PMC: 11843704. DOI: 10.1177/17534666251318615.

References
1.
Hellmich B, Sanchez-Alamo B, Schirmer J, Berti A, Blockmans D, Cid M . EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023; 83(1):30-47. DOI: 10.1136/ard-2022-223764. View

2.
Levy M, Bacharier L, Bateman E, Boulet L, Brightling C, Buhl R . Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. NPJ Prim Care Respir Med. 2023; 33(1):7. PMC: 9907191. DOI: 10.1038/s41533-023-00330-1. View

3.
Lugogo N, Mohan A . Are We Poised to Change the Trajectory of Maintenance Oral Corticosteroid Use in Severe Asthma in the Age of Biologics?. Chest. 2022; 162(1):4-5. DOI: 10.1016/j.chest.2022.04.004. View

4.
Castro M, Zangrilli J, Wechsler M, Bateman E, Brusselle G, Bardin P . Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015; 3(5):355-66. DOI: 10.1016/S2213-2600(15)00042-9. View

5.
Bachert C, Han J, Wagenmann M, Hosemann W, Lee S, Backer V . EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J Allergy Clin Immunol. 2020; 147(1):29-36. DOI: 10.1016/j.jaci.2020.11.013. View